| Assay ID | Title | Year | Journal | Article |
|---|
| AID641816 | Inhibition of MMP8 expressed in CHO-K1 cells using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641814 | Inhibition of MMP1 expressed in Escherichia coli using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169679 | Inhibition of recombinant human caspase 2 using DEVDAA substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169684 | Inhibition of recombinant human cathepsin K using HHQKLVFFAE substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169719 | Inhibition of CYP2C8 (unknown origin) using amodiaquine substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641887 | Inhibition of MMP14 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641813 | Inhibition of TACE at 40 uM | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641881 | Inhibition of MMP1 expressed in Escherichia coli assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169711 | Inhibition of CYP2C8 (unknown origin) using amodiaquine substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169672 | Inhibition of recombinant human MMP-9 using GRIGFL substrate up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169712 | Inhibition of CYP2C9 (unknown origin) using diclofenac substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169717 | Inhibition of CYP1A2 (unknown origin) using tacrin substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641884 | Inhibition of MMP8 expressed in CHO-K1 cells assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169688 | Inhibition of recombinant human furin using RRVKRSLD substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169716 | Inhibition of CYP3A4 (unknown origin) using testosterone substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169707 | Half life in mouse liver microsomes by LC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169678 | Inhibition of recombinant human caspase 1 using WEHDGPKR substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169715 | Inhibition of CYP3A4 (unknown origin) using midazolam substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169720 | Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169673 | Inhibition of recombinant human MMP-12 using GRIGFL substrate up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169722 | Inhibition of CYP2D6 (unknown origin) using dextromethophan substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169723 | Inhibition of CYP3A4 (unknown origin) using midazolam substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169680 | Inhibition of recombinant human caspase 3 using DEVDAA substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641817 | Inhibition of recombinant MMP9 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169677 | Inhibition of recombinant human cathepsin D using EVNLDAEFRK substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169670 | Inhibition of recombinant human MMP-2 using GRIGFL substrate up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641888 | Inhibition of MMP20 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169718 | Inhibition of CYP2B6 (unknown origin) using bupropion substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169706 | Half life in human liver microsomes by LC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641815 | Inhibition of human MMP2 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641882 | Inhibition of human MMP2 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169667 | Inhibition of full-length recombinant human MMP-13 assessed as bovine type-2 collagen hydrolysis after 18 hrs by ELISA | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169708 | Half life in rat liver microsomes by LC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169690 | Inhibition of recombinant human uPA using GRTSSVEP substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169713 | Inhibition of CYP2C19 (unknown origin) using (S)-mephentoin substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169689 | Inhibition of recombinant human thrombin using PRTLT substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641879 | Inhibition of MMP1 expressed in Escherichia coli using triple-helical fTHP-15 as substrate after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169685 | Inhibition of recombinant human cathepsin L using GGALRAG substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641886 | Inhibition of human full length recombinant MMP13 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641885 | Inhibition of MMP12 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169668 | Inhibition of full-length recombinant human MMP-13 assessed as prevention of bovine type-2 collagen degradation at 10 uM after 18 hrs by cartilage explant assay | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169674 | Inhibition of recombinant human ACE using RPFNYLAK substrate up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169683 | Inhibition of recombinant human caspase 7 using DEVDAA substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169686 | Inhibition of recombinant human cathepsin S using RTLTAK substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169681 | Inhibition of recombinant human caspase 5 using LEHDGP substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641818 | Inhibition of MMP14 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169682 | Inhibition of recombinant human caspase 6 using VEHDGG substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169675 | Inhibition of recombinant human MMP-13 using GRIGFL substrate assessed as inhibition of enzyme activity up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169710 | Inhibition of CYP2B6 (unknown origin) using bupropion substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169714 | Inhibition of CYP2D6 (unknown origin) using dextromethophan substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169721 | Inhibition of CYP2C19 (unknown origin) using (S)-mephentoin substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641883 | Inhibition of MMP3 expressed in Escherichia coli assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169671 | Inhibition of recombinant human MMP-3 using GRIGFL substrate up to 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169687 | Inhibition of recombinant human factor 10a using ALPRTMFIQ substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169709 | Inhibition of CYP1A2 (unknown origin) using tacrin substrate | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641880 | Inhibition of MMP8 expressed in CHO-K1 cells using triple-helical fTHP-15 as substrate after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID1169664 | Non-competitive inhibition of full-length recombinant human MMP-13 assessed as fTHP-15 substrate hydrolysis | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169665 | Non-competitive inhibition of full-length recombinant human MMP-13 assessed as fTHP-15 substrate hydrolysis by Lineweaver-Burke plot analysis | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169724 | Inhibition of CYP3A4 (unknown origin) using testosterone substrate at 20 uM | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID1169676 | Inhibition of recombinant human BACE1 using SEVNLDAEFRKKRR substrate at up to 20 uM after 3 hrs | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
| Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. |
| AID641811 | Inhibition of human full length recombinant MMP13 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID641812 | Noncompetitive inhibition of human full length recombinant MMP13 using triple-helical fTHP-15 as substrate by Lineweaver-Burk plot analysis | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
| Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |